Direct renin inhibitors as a new therapy for hypertension.
Webb
Randy L
RL
Novartis Pharmaceuticals Corp, Institutes for BioMedical Research, East Hanover, New Jersey, USA.
Schiering
Nikolaus
N
Sedrani
Richard
R
Maibaum
Jürgen
J
D000818:Animals; D000959:Antihypertensive Agents / Q000737:chemistry* / Q000494:pharmacology; D001665:Binding Sites; D018360:Crystallography, X-Ray; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008958:Models, Molecular; D015394:Molecular Structure; D057786:Peptidomimetics / Q000737:chemistry* / Q000494:pharmacology; D010880:Piperidines / Q000737:chemistry / Q000494:pharmacology; D011956:Receptors, Cell Surface / Q000819:agonists / Q000378:metabolism; D012083:Renin / Q000378:metabolism; D013329:Structure-Activity Relationship; D000093342:Prorenin Receptor; D000092502:Renin Inhibitors
D000959:Antihypertensive Agents; D057786:Peptidomimetics; D010880:Piperidines; D011956:Receptors, Cell Surface; D012083:Renin; D000093342:Prorenin Receptor; D000092502:Renin Inhibitors